AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis

Phase 2 Unknown 20 enrolled Daval International Limited

RandomizedCrossoverQuadruple-blindTreatment

Summary

Patients with marked bladder dysfunction as a result of secondary progressive multiple sclerosis are being recruited to receive AIMSPRO or placebo by subcutaneous injection, in this double-blind crossover study.

Timeline

Start: 2009-05
Primary completion: 2011-05
Completion: 2012-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AIMSPRO	Protein / enzyme biologic	1 ml	Subcutaneous

AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis

Summary

Timeline

Drugs

Indications